REFERENCES
- Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857): a potent, orally bioavailable and selective small-molecule inhibitor of the chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721–4732.
- Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine/lamivu-dine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1. J Infect Dis. 2010;201:803–813.
- Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51:566–575.
- Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. An enhanced-sensitivity TrofileTm HIV coreceptor tropism assay for selecting patients for therapy with entry inhibi-tors targeting CCR5: a review of analytical and clinical studies. J Viral Entry. 2009;3:94–102.
- Trinh L, Han D, Huang W, et al. Technical validation of an enhanced sensitivity Trofle HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antiyir Ther 2008;13(Suppl 3):A128.
- DHHS/FDA/CDER Guidance For Industry: Antiretrovi-ral drugs using plasma RNA measurements - clinical considerations for accelerated and traditional approval. 2002. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ ucm070968.pdf. Accessed November 19,2009.
- Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–2106.
- Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796–806.
- Wilkin T, Ribaudo H, Gulick R. The relationship of CCR5 inhibitors to CD4 cell count changes: a meta-analysis of recent clinical trials. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, USA, February 3–6, 2008. Abstract 800.
- Asmuth DM, Goodrich J, Cooper DA, et al. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2 [published online ahead of print December 9,2009]. J Acquir Immune Defic Syndr doi: 10.1097/QA1.0b013e3181c5c83b.
- Lazzzarin A, Battegay M, Cooper DA, et al. CD4+ cell increases at 48 weeks in the maraviroc treatment-naïve MERIT trial. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meet-ing of the Infectious Diseases Society of America; October 26–28, 2008; Washington, DC, USA. Abstract H–1248.
- Zolopa A, Andersen J, Powderly W, et al. Early antiretrovi-ral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter random-ized strategy trial. PLoS One. 2009;4:e5575.
- Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441–446.
- When to Start Consortium. Timing of initiation of anti-retroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1314–1316.